Check out your Company Bowl for anonymous work chats.
~95% of Amplity’s outsourced field commercial programs have integrated remote engagement solutions. Our blended engagement model leverages the benefits of remote and in-person engagement to optimize the communication mix across personal and non-personal channels, ultimately delivering relevant, timely, and credible information to HCPs when and where they want it.
The SEER Program of the NCI estimates 26,500 new cases of stomach cancer will be diagnosed in the US in 2023. These numbers remind us of the urgency of advancing therapies and treatments. We're proud to collaborate with our pharmaceutical clients who are working tirelessly to develop groundbreaking therapeutics for gastric cancer patients. Together, we're committed to improving the lives of those affected by this disease. #StomachCancerAwarenessMonth #GastricCancerAwarenessMonth
Amplity's Market Access team will be attending the AMSUS Sustaining Members conference December 6-7 in Crystal City, VA. As industry leaders in federal access strategy, we're attending AMSUS to meet with life science companies seeking an experienced partner to help them navigate the VA, DoD, and federal contracting. Meet with Bruce Valentine and Nikolina Janakievski to find out how Amplity Market Access consulting can improve your business in the VA and DoD.
Amplity's Samantha DiClementi, a first-year HBA member, is gearing up to attend her very first #HBA Annual Conference. As she embarks on this incredible journey, Samantha shares her enthusiasm: "I am eager to acquire skills and behaviors that will enhance my leadership abilities, enabling me to foster greater self-awareness, and cultivate improved behaviors and workplace culture within my team and company." Amplity is committed to supporting our team members in their growth, and we can't wait to see the positive impact Samantha will make at #HBA23. #powerthepossibilities
Compliance should not hinder profitability but should be a means to ensure it. If you’re a small to medium-sized pharma company launching a product for the first time, you need a compliance partner who deeply understands both the pharma industry and your company's unique business goals. Amplity’s Director of Compliance, Keysha Bradford, can help. Start by reading her latest article on how to conduct a readiness assessment, identify commercial risks, and establish a compliance program that aligns with the OIG's recommendations: https://lnkd.in/eFdVyFqx. Then contact Keysha to learn how and why we’re best!
Please join us in welcoming Michele to Amplity as Head of Learning Solutions! Visit https://lnkd.in/g7f5QYvw to learn how Michele’s appointment further strengthens our ability to deliver exceptional learning experiences that drive high performance for our pharmaceutical clients.
The federal healthcare market truly offers a unique opportunity for life science and health technology companies if they understand how it functions. Amplity's David (Dave) W. Bobb - Principal, Market Access, answers the most common questions he receives from our clients looking for guidance on their federal access strategy. Visit https://lnkd.in/eG5w7tdQ to read the FAQ, then contact Dave to learn how you can leverage his experience as a former Defense Health Agency’s Chief of Pharmacy Operations for your market access strategy.
We're passionate about empowering our team members, which is why we're thrilled to be attending #HBA23 next month. Amplity's Erica Smith explained, "In addition to creating new connections with fellow HBA members, I am really looking forward to participating in the Bold Practices Breakout Sessions to gather innovative ideas and actionable strategies to achieving gender equity in the workplace." #HBA #powerthepossibilities #HBA23
Research reveals that ~64% of potentially eligible patients are not benefiting from precision oncology therapies. As a solutions provider committed to improving the landscape of personalized medicine, we recognize the urgency of addressing clinical practice gaps. Our newest article details the challenges pharmaceutical companies commonly face when integrating predictive biomarker testing into clinical care. Read the article here: https://lnkd.in/e3Vc2zUF
The purpose of the #BreastCancerAwarenessMonth national campaign, which encompasses a wide range of initiatives conducted by local community organizations, breast cancer advocacy organizations, and major retailers, is to educate the public about breast cancer risk factors, promote screening and prevention, support individuals diagnosed with the disease and their loved ones, and raise funds for breast cancer research. Read more: https://bit.ly/46Wr3lA
